

Original Research Article

<https://doi.org/10.20546/ijcmas.2017.605.278>

Prevalence of *Helicobacter pylori* Antibodies in Egyptians with Idiopathic Thrombocytopenic purpura and in the General Egyptian Population: A Comparative Study

Nesren F. Hanafi¹, Irene L. Mikhael² and Doreen N. Younan^{3*}

¹Department of Microbiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt

²Department of Haematology, Medical Research Institute, Alexandria University, Alexandria, Egypt

³Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt

*Corresponding author email id:

ABSTRACT

Keywords

Helicobacter pylori, Seropositivity, ITP, Autoimmune disease, Platelets

Article Info

Accepted:
25 April 2017
Available Online:
10 May 2017

This study is a survey to reveal the sero-positivity rate of *H. pylori* in ITP, versus healthy Egyptians. We also aimed at correlating *H. pylori* antibody titre with the severity of ITP. This study included 293 Egyptians; 135 ITP patients and a control group of 158 individuals. CBC was done to determine platelet counts. Quantitative determination of *H. pylori* IgM and IgG was performed using Monobind, ELISA kit. Sero-positivity for *H. pylori* IgM among controls (54.4%) was found to be significantly higher than among ITP patients (28.9%), $p=0.0001$. However, there was no significant difference between sero-positivity for *H. pylori* IgG among controls (79.7%) and ITP patients (77.7%), $p=0.680$. A significantly higher mean level of IgG antibodies was detected among ITP patients (96.27 U/ml) compared to controls (83.735 U/ml), $p=0.001$. A significant negative correlation existed between *H. pylori* IgM, IgG titres and platelet counts of ITP patients, $r=-0.34$ & $r=-0.385$, respectively, $p = 0.001$. The sero-prevalence of *H. pylori* infection is high among Egyptians. Our results confirm reports proposing that antibodies produced against *H. pylori* infection might cross react with platelet antigens. ITP patients should be tested for *H. pylori* antibodies to receive triple therapy.

Introduction

Immune thrombocytopenic purpura (ITP) is an autoimmune bleeding disorder resulting from antibodies against platelet surface glycoproteins, resulting in their destruction. Several microbial agents causing chronic infections, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV) and helicobacter pylori (*H. pylori*) have been

shown to be associated with ITP (Hasni, 2012).

Previous studies suggest that infectious agents may influence the occurrence or the course of some autoimmune diseases (Rizzo *et al.*, 2014). There are several proposed mechanisms by which microbial organisms

can lead to loss of self-tolerance; such as molecular-mimicry, when shared amino acid sequences between microbial antigens and host proteins lead to generalized triggering of immune response against both the host proteins and microbial antigens (Cooke *et al.*, 2008). Other proposed mechanisms leading to triggering of autoimmunity include polyclonal activation, epitope spread, bystander activation and super-antigens (Amital *et al.*, 2008).

Helicobacter pylori are widely prevalent, spiral Gram negative bacteria which were discovered, as human pathogens, by Marshall and Warren in 1982 [Marshall and Warren, 1984]. Studies have indicated that *H pylori* typically infect the gastric mucosa, and so their presence is associated with a variety of gastrointestinal diseases including gastritis, duodenal and gastric ulcers, non-ulcer dyspepsia, and gastric adenocarcinoma and lymphoma (Zhong *et al.*, 2016).

Helicobacter pylori infection has a high prevalence globally, ranging from 50 to 80%. Usually acquired early in life, it is characterized by long incubation period. Most of the infected cases remain asymptomatic for decades. Clinically presented cases are commonly associated with gastritis and peptic ulcer disease (Kao *et al.*, 2016).

Infected hosts' immune response, not only fails to resolve the infection, but may contribute to the severity of the disease. This pathogenicity involves stimulation of T helper one induced inflammation. Some studies document that *H pylori* infection down regulates the host's immune response and also some researchers suggest the contribution of *H pylori* to some autoimmune disease' development (Hasni *et al.*, 2011). Multiple publications have attributed a role for *H. pylori* infection in causing a variety of extra-intestinal manifestations (Sherman *et al.*,

2005), (Wong *et al.*, 2014), (Bruscky *et al.*, 2014).

Effective diagnostic modalities and treatment strategies are currently available and have proven to be effective in detecting and eradicating of *H pylori* infections. Organism removal by antimicrobial therapy is correlated with the resolution of symptoms and cure of the disease. However, traditional treatments of ITP involve the use of immunosuppressive agents and immunoglobulin therapy (Shmueli *et al.*, 2016).

In spite of the conflicting data, some researchers reported high association of *H pylori* infection prevalence with many autoimmune diseases such as ITP, atrophic gastritis and mucosa associated lymphoid tissue (MALT) lymphoma. Autoimmune diseases' unclear etiology has been justified by the hypothesis of being induced due to exposure to viral, bacterial or chemical agents, in a genetically predisposed individual (Hasni, 2012).

The present study aims at reporting the prevalence of *H pylori* antibodies (IgM and IgG) in the general Egyptian population and in ITP patients and, also, determines the correlation between quantitative estimation of their titre in sera of infected ITP patients and severity of thrombocytopenia.

Materials and Methods

Study design

Cross-sectional observational study.

Subjects

The present work was conducted in Alexandria University Teaching Hospital and Medical Research Institute, in Northern Egypt. This study received ethical approval

from the Institutional Review Board at Faculty of Medicine, Alexandria University in Egypt and written informed consents were obtained from all participants before enrollment in the study. The identification information of all subjects was kept confidential and was protected from the public. This work has been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.

One hundred and thirty five adult ITP patients (above 18 years of age), presented to the Haematology Clinic at Medical Research Institute of Alexandria, were recruited in this case-control study. They comprised 90 females and 45 males (male to female ratio of 0.5:1), their ages ranged between 18 and 56 years.

Immune thrombocytopenic purpura was diagnosed on the basis of the presence of isolated thrombocytopenia ($<100 \times 10^9/L$) with or without megakaryocytic hyperplasia in the bone marrow. Other causes of thrombocytopenia (drugs, pseudo-thrombocytopenia, HBV, HCV, HIV, malignancy and collagenic diseases) were all excluded.

One hundred and fifty eight age and sex matched Egyptians served as a control group. They comprised 84 females and 74 males with a male to female ratio of 0.9:1, their ages ranged between 18 and 57 years. They were all non-thrombocytopenic, apparently healthy without dyspeptic complaints.

None of the included subjects had previously received antibiotics (commonly used in anti-*H. pylori* therapy), H₂ blockers or proton pump inhibitors (PPIs) in the three months preceding this study. Patients with history of gastric resection/ vagotomy, those with complicated peptic ulcer disease and those

considered at bleeding risk, were also excluded.

Laboratory tests (Hasni, 2012)

Quantitative determination of *H. pylori* specific antibodies of the IgM and IgG types, in sera of both ITP patients and controls, was done in Alexandria University Teaching Hospital, using commercial enzyme immunoassay kits (Accu Bind ELISA micro wells, product codes; 1525-300 IgM and 1425-300 IgG, Monobind Inc, Lake Forest, CA 92630, USA). The reagents were stored unopened at 40C. Repeated freezing and thawing of sera was avoided. Icteric and turbid samples were not used (manufacturer's precautionary advice). A reference curve was drawn on a linear graph paper; using 5 anti *H. pylori* calibrators supplied within the kit, to determine the concentration of *H. pylori* IgM and IgG in unknown specimens (Hasni *et al.*, 2011).

The presence of IgG antibodies to *H. pylori* was documented when the serum level exceeds 20 U/ml while the presence of IgM antibodies to *H. pylori* was documented when the serum level exceeds 40 U/ml (according to manufacturer's recommendations). Specimens with concentrations greater than 100 U/ml were additionally diluted 1:5 or 1:10 with the supplied serum diluent and the final result was obtained after multiplication by the dilution factor. A positive result does not indicate gastrointestinal disease and does not distinguish between colonization and infection. Similarly, a negative result does not eliminate the absence of *H. pylori* infection. A low titre of antibody may be related to early stages of colonization.

Complete blood counts (CBCs) were done by Sysmex® STKS (Coulter Corporation Miami, Florida, USA). Bone marrow aspiration was done to selected ITP patients.

Although the presence of *H pylori* bacilli in gastric biopsies is the gold standard of *H pylori* detection, we preferred blood antibody detection due to following reasons; endoscopy might cause unexpected bleeding in thrombocytopenic patients, especially in those whose platelet counts are less than $50 \times 10^9/L$, and urea breath test could not allow the detection of *H pylori* infection retrospectively.

Statistical Analyses (Binu *et al.*, 2014)

Data were collected, tabulated and statistically analyzed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA) and Microsoft Office Excel 2010 (Microsoft Cor., Redmond, WA, USA). Continuous data are expressed as mean \pm SD and median (range). Categorical data are expressed as a number (percentage). Continuous variables were checked for normality by Kolmogorov-Smirnov test. Mann-Whitney U test was used to compare two groups of non-normally distributed data and independent t test for parametric data. Percent of categorical variables were compared using Chi-square (χ^2) test and Fischer exact test for $>50\%$ of cell count < 5 . Comparing studied groups, one way ANOVA test was used for parametric data and Kruskal Wallis test for non-parametric data. Spearman correlation was done for non-parametric correlation between Ig titres and platelet counts. All tests were two tailed. $p \leq 0.05$ was considered statistically significant, $p < 0.01$ was considered highly statistically significant and $p > 0.05$ was considered non-statistically significant.

Results and Discussion

The present study comprised 135 ITP patients; 45 males (33.3%) and 90 females (66.7%) with a mean age \pm SD of 30.3 years \pm 9.6. A control group of 158 healthy volunteers; 74 males (46.8%) and 84 females

(53.2%) have been included matched for age ($p = 0.698$) and sex ($p = 0.101$). The platelet counts of ITP patients ranged between 3,000 and 104,000/cmm with a mean \pm SD of $29,333/cmm \pm 23,662$, while those of healthy controls ranged between 159,000 and 560,000/cmm with a mean \pm SD of $354,300/cmm \pm 30,501$.

The prevalence of seropositivity for anti-helicobacter IgM among healthy controls was 54.4 % (86/ 158), while it was lower among ITP patients; 28.9% (39/ 135), without a statistical significant difference between the 2 groups ($p=0.291$). On the other hand, the prevalence of anti-helicobacter IgG was lower among ITP patients; 77.8 % (105/ 135) compared with controls; 79.8% (126/ 158), still with no statistical significant difference revealed ($p=0.680$), as shown in table 1.

The prevalence of anti-helicobacter IgM among all sero-positive ITP patients was found to be 36.1%, while that among sero-positive controls was 60.6%, $p=0.004^*$. For anti-helicobacter IgG, it was found to be 97.2% among all sero-positive ITP patients and 88.7% among sero-positive controls, $p=0.54$. (Table 1)

Furthermore, platelet counts of *H. pylori* sero-positive ITP patients was found to be significantly lower than that of *H. pylori* sero-negative ITP patients ($p < 0.05$) (Table 2).

Intending to study the effect of chronic or past *H pylori* infection, we excluded IgM positive cases in both groups (as presence of IgM denotes acute infection). The comparison revealed a statistical significant increase in ITP cases; 51.1% (69 out of 135) versus 35.4% among controls (56 out of 158) who were concomitantly IgG positive and IgM negative (denoting past or chronic infection) ($X^2 = 22.3$, $p = 0.0001$). While, IgM only positive cases (denoting a recent or acute

infection, evidenced by absence of concomitant IgG positivity), were found to be significantly lower among ITP patients; 2.2% (3/135) versus controls; 10.1% (16/158), $p=0.002^*$. [Table 3]

On comparing the quantitative estimation of antibodies in sera (Table 4), a significantly higher mean level for anti *H. pylori* IgM antibodies was revealed among controls (mean \pm SD 72.14 U/ml \pm 22.17), compared to ITP patients (mean \pm SD 56.57 U/ml \pm 10.85) with a p value of 0.013. However, a higher mean level of IgG antibodies was detected among ITP patients (96.27 U/ml \pm 24.15) when compared to controls (83.73 U/ml \pm 38.37), but without a statistical significance difference between both groups, $p = 0.098$.

On studying the correlation coefficient between the quantitative determination of *H. pylori* IgM and IgG antibodies on one hand and platelet counts of ITP patients on the other, our study proved a statistically significant negative correlation between them i.e. an increase in antibody titre, whether IgM or IgG, is associated with a decrease in platelet counts among ITP patients, with a p value of 0.0001 for both, as shown in table 5 and figure 1.

The relationship between *H. pylori* and other autoimmune diseases, such as ITP, has motivated us to find out if there is any correlation between anti-*H. pylori* IgM and IgG titres and severity of thrombocytopenia in those patients as a part of studying the pathogenesis of this disease and predicting the cure when administering anti-*H. pylori* therapy.

The role of *H. pylori* in the pathogenesis of ITP has been suggested because significant increases in platelet counts were reported after *H. pylori* eradication. However, the role

of *H. pylori* in the pathogenesis of ITP is still controversial. Several studies have attempted to explain the underlying pathogenic mechanism of *H. pylori* induced ITP. Most prevailing hypothesis suggests molecular mimicry between one of the *H. pylori* antigens and platelet glycoproteins is causing production of cross-reacting auto-antibodies (Franchini *et al.*, 2010).

H. pylori are distributed worldwide, though the prevalence strongly varies between developing and developed countries; it is more than 80 and 30%, respectively. An Indian report indicates that almost 80% of the population is infected with *H. pylori* (Poddar and Yaccha, 2007).

Regarding the association between *H. pylori* and ITP, Gasbarrini *et al.*, (Gasbarrini *et al.*, 1998) reported that 61% of 18 ITP cases were infected with *H. pylori*. Since this report by Gasbarrini *et al.*, an accumulating body of evidence has proposed a patho-physiological link between ITP and chronic *H. pylori* infection. Clinical reports have described a spontaneous resolution of ITP symptoms in about 50% of chronic ITP patients following empirical treatment of *H. pylori* infection. Emilia *et al.*, (Emilia *et al.*, 2001) then reported that 43% of 30 ITP patients were *H. pylori* positive. The prevalence of *H. pylori* infection in healthy population of Italy, where Gasbarrini's and Emilia's studies were held, was about 63% (Luzza *et al.*, 1998).

In our study, the prevalence of *H. pylori* seropositivity in ITP patients was 80%, lower than that in the general population \approx 90%. Moreover, *H. pylori* IgG sero-positivity was present in \approx 78% of ITP patients and in \approx 80% of the general population; however, IgM sero-positivity was present in \approx 29% of ITP patients and in \approx 54% of the general population. Thus, there was no significant increase in sero-prevalence of *H. pylori* among

ITP patients. Both IgM and IgG titres showed significant negative correlation with the severity of thrombocytopenia in our ITP patients ($r = -.340$ and $-.385$, respectively, $p = 0.001$ for both).

The finding of low prevalence of ITP among acutely infected individuals and higher prevalence of ITP among those with long-standing infection is acceptable to justify the proposed hypothesis that prolonged exposure to high level of antibodies would contribute to the development of the autoimmune disease. This agrees with researchers disclaiming any direct relation of acute infection with ITP pathogenesis.

Furthermore, this has been confirmed by the significantly negative correlation coefficient revealed between *H. pylori* IgG antibody titres and platelet counts, among ITP patients. These data would be of great benefit for clinicians for better understanding of ITP aetiology, thus improving management of such cases and their outcome.

We have proved that *H. pylori* IgM and IgG seropositivity is very common and widely spread in Egypt. The prevalence of *H. pylori* seropositivity among adults in this Northern Egyptian community is 89.9%, which is relatively high when compared to its prevalence elsewhere.

This is mostly attributed to the low socioeconomic status, poor human and domestic waste disposal systems and household crowding, which are the main factors that enhance the infection. The high percentages documented in our study can, also, be explained by the reporting of Shukla *et al.*, (Shukla *et al.*, 2012) that “ELISA, if done alone, may overestimate the presence of active *H. pylori* infection as antibody titres can remain elevated even after the eradication of *H. pylori*”.

Michel *et al.*, (Michel *et al.*, 2002) and Jargue *et al.*, (Jargue *et al.*, 2001) found no evidence of an association between *H. pylori* infection and ITP. Kohda *et al.*, (Kohda *et al.*, 2002) found that *H. pylori* were positive in 62.5% of 40 ITP patients in Japan, where the prevalence of *H. pylori* infection ranged between 25-45%. Kurtoglu *et al.*, (Kurtoglu *et al.*, 2004) found *H. pylori* infection in 65.2% of healthy Turkish individuals, while its prevalence in Turkish ITP patients was 68.5%.

Kohda *et al.* (Kohda *et al.*, 2002) and Michel *et al.* (Michel *et al.*, 2002) found no significant difference in platelet counts between *H. pylori*-positive and *H. pylori*-negative ITP patients. However, in our study, we found a statistically significant decrease in platelet counts among *H. pylori* sero-positive ITP patients when compared with their sero-negative counterparts, $p < 0.05$. Contrary to our findings, the study carried out by Kurtoglu *et al.*, (Kurtoglu *et al.*, 2004) revealed higher platelet counts among *H. pylori* positive group than *H. pylori*-negative group at the initial presentation, and the difference between the two groups was significant ($p < 0.05$).

In the review done by Stasi *et al.*, (Stasi *et al.*, 2009), they reported worldwide prevalence of *H. pylori* in ITP patients from 25 studies. The result from these studies revealed an overall prevalence of 62.3%. However, when matched with age and geographic area, the prevalence rate of *H. pylori* infection, in most of these studies, were similar to the healthy population. Similarly, Liebman (Liebman, 2007) showed that the prevalence of *H. pylori* infection in patients with ITP was similar to controls matched for age and geographical location. Also, we found the sero-prevalence of *H. pylori* infection to be 80% and 89% in ITP patients and healthy controls respectively.

Table.1 Distribution of cases and controls according to *H. pylori* sero-positivity

	ITP patients (n =135)	Controls (n=158)	p
Total seropositive subjects	108/135 (80%)	142/158 (89.9%)	0.78
IgM positive subjects (n)	39	86	0.004*
-% of seropositive subjects	39/108 (36.1%)	86/142 (60.6%)	
-% of total	39/135 (28.9%)	86/ 158 (54.4%)	
IgG positive subjects (n)	105	126	0.54
-% of seropositive subjects	105/108 (97.2%)	126/142 (88.7%)	
-% of total	105/135 (77.8%)	126/158 (79.8%)	

ITP: Immune thrombocytopenic purpura

p: significant if < 0.05

Table.2 Comparison between *H. pylori* sero-positive and sero-negative ITP patients

	<i>H. pylori</i> seropositive ITP Patients	<i>H. pylori</i> seronegative ITP Patients	p
Number of Patients	108/135 (80%)	27/135 (20%)	
Platelet count (x10³/cmm) mean (range)	27.3 (3-96)	37.4 (12-104)	P<0.05

H pylori = Helicobacter pylori

ITP: Immune thrombocytopenic purpura

p: significant if < 0.05

Table.3 Incidence of seropositivity of *H. Pylori* IgM and IgG antibodies in both studied groups

<i>H pylori</i> Seropositivity (IgM, IgG)		Groups		X²
		Controls (n= 158)	ITP (n= 135)	
Both -ve	n	16	27	0.052
	%	10.1%	20%	
IgM-ve, IgG +ve	n	56	69	0.037
	%	35.4%	51.1%	
Both +ve	n	70	36	0.003*
	%	44.3%	26.7%	
IgM+ve, IgG-ve	n	16	3	0.002*
	%	10.1%	2.2%	
Total	n	158	135	293
	%	100.0%	100.0%	100.0%

H pylori = Helicobacter pylori

IgG = Immunoglobulin G

IgM = Immunoglobulin M

ITP = Idiopathic thrombocytopenic purpura

p: significant if < 0.05

Table.4 Comparison between cases and controls regarding *H pylori* IgM and IgG positive titres

H pylori Seropositivity	ITP (n=135)	Controls (n=158)	t, p
IgM (U/ml)			
Range	42 - 77	40- 116.53	
Mean ± SD	56.57 ± 10.85	72.14 ± 22.17	t=3.08, p=0.013*
IgG (U/ml)			
Range	21 – 140	23 - 131.3	
Mean ± SD	96.27 ± 24.15	83.73 ± 38.37	(t=1.65, p=0.098).

H. pylori = Helicobacter pylori

IgG = Immunoglobulin G

IgM= Immunoglobulin M

p: significant if < 0.05

Table.5 Correlation between platelet counts and both *H. pylori* IgM and IgG titres among ITP patients

	Platelet Counts of ITP Patients	
	r	p
H pylori IgM Titre	-.340**	.0001
H pylori IgG Titre	-.385**	.0001

H pylori = Helicobacter pylori

IgG = Immunoglobulin G


IgM = Immunoglobulin M

ITP = Idiopathic thrombocytopenic purpura

r= correlation

p: significant if < 0.05

Fig.1 Graphical representation of the negative correlation between *H. pylori* IgG titre and platelet counts among ITP patients



We hypothesized that the severity of ITP might depend on the density of *H. pylori* antibodies i.e. anti-*H. pylori* antibody titre, since bacterial eradication has been proved, by previous studies, to result in platelet count improvement. Serum ELISA for IgM and IgG antibodies against *H. pylori*, done in our study, correlated significantly ($p < 0.001$) with the severity of thrombocytopenia, which was comparable to a study by Kate *et al.*, (Kate and Ananthakrishnan, 2000).

Studies have also documented that ITP patients in East Asian countries are more likely to express positive antibody titers against *H. pylori*-specific cytotoxic-associated gene A (CagA), a virulence factor that is associated with an increased risk for gastric diseases including carcinoma. While a definitive mechanism by which *H. pylori* may induce thrombocytopenia remains elusive, proposed pathways include molecular mimicry of CagA by host auto antibodies against platelet surface glycoproteins, as well as alterations in the phagocytic activity of monocytes (Frydman *et al.*, 2015).

Results of Abdollahi *et al.*, (Abdollahi *et al.*, 2015) strongly support the role of *H. pylori* in ITP children, by demonstrating a statistically significant higher prevalence of *H. pylori* stool Ag in ITP cases than in controls. Among the weak points of our study, are the relatively small sample size and antibody quantitation by ELISA, which might overestimate the presence of active *H. pylori* infection, as antibody titers can remain elevated even after the eradication of *H. pylori*. However, among the strong points, are the same ethnic origin of the population studied; all Egyptians from Northern Egypt, and the significant negative correlation found between quantitative estimation of *H. pylori* Ig titers and platelet counts among ITP patients. Further research on the immunological responses to infectious agents, including *H. pylori*, is still needed. We

strongly support the proposal that the detection and eradication of *H. pylori* could be an effective means for treating ITP. This will, surely, require extensive studies to confirm the suggested causative relationship between bacterial infection and an autoimmune disease state.

In conclusion, the diagnostic work-up for patients with ITP should include tests to detect the presence of *H. pylori* and to quantitate their antibodies. This conclusion is confirmed by the results of our study. We further recommend that patients with thrombocytopenia, who are also infected with *H. pylori*, should be treated with traditional triple therapy. *H. pylori* IgM and IgG seropositivity is very common and widely spread in Egypt. The prevalence of *H. pylori* seropositivity among adults in this Northern Egyptian community is 89.9%, which is relatively high when compared to its prevalence elsewhere. The incidence of seropositivity for anti-*Helicobacter* IgM among controls was found to be significantly higher than among ITP patients. Serum IgM and IgG antibodies against *H. pylori* correlate significantly with the severity of thrombocytopenia. *H. pylori* infection should be searched in all ITP patients, and we suggest that it should be eradicated in all *H. pylori*-positive ITP patients.

Acknowledgement

All authors have fulfilled the following: Substantial contributions to research design, the acquisition, analysis and interpretation of data, Drafting the paper and revising it critically, approval of the submitted and final versions.

References

Abdollahi, A., Shoar, S., Ghasemi, S., *et al.*, 2015. Is *Helicobacter pylori* infection a risk factor for idiopathic

- thrombocytopenic purpura in children? *Ann. Afr. Med.*, 14: 177-181.
- Amital, H., Govoni, M., Maya, R., *et al.*, 2008. Role of infectious agents in systemic rheumatic diseases. *Clin. Exp. Rheumatol.*, 26: S27-S32.
- Binu, V.S., Mayya, S.S., Dhar, M. 2014. Some basic aspects of statistical methods and sample size determination in health science research. *Ayu*, 35: 119-123.
- Bruscky, D.M., da Rocha, L.A., Costa, A.J. 2013. Recurrence of chronic urticaria caused by re-infection by helicobacter pylori. *Rev. Paul. Pediatr.*, 31: 272-275.
- Cooke, A., Ferraccioli, G.F., Herrmann, M., *et al.*, 2008. Induction and protection of autoimmune rheumatic diseases, the role of infections. *Clin. Exp. Rheumatol.*, 26: S1-7.
- Emilia, G., Longo, G., Luppi, M., *et al.*, 2001. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. *Blood*, 97: 812-814.
- Franchini, M., Plebani, M., Montagnana, M., *et al.*, 2010. Pathogenesis, laboratory, and clinical characteristics of helicobacter pylori -associated immune thrombocytopenic purpura. *Adv. Clin. Chem.*, 52: 131-144.
- Frydman, G.H., Davis, N., Beck, P.L., *et al.*, 2015. Helicobacter pylori eradication in patients with immune thrombocytopenic purpura: A review and the role of biogeography. *Helicobacter*, 20: 239-251.
- Gasbarrini, A., Franceschi, F., Tartaglione, R., *et al.*, 1998. Regression of autoimmune thrombocytopenia after eradication of helicobacter pylori. *Lancet*, 352: 878.
- Hasni, S., Ippolito, A., Illei, G.G. 2011. Helicobacter pylori and autoimmune diseases. *Oral Dis.*, 17: 621-627.
- Hasni, S.A. 2012. Role of Helicobacter pylori infection in autoimmune diseases. *Curr. Opin. Rheumatol.*, 24: 429-434.
- Jargue, I., Andreu, R., Llopis, I., *et al.*, 2001. Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura. *Br. J. Haematol.*, 115: 1002-1003.
- Kao, C.Y., Sheu, B.S., Wu, J.J. 2016. Pathogenesis. *Biomed. J.*, 39: 14-23.
- Kate, V., Ananthakrishnan, N. 2000. Helicobacter pylori and gastric carcinoma: Evidence for the link. *Natl. Med. J. India*, 13: 329.
- Kohda, K., Kuga, T., Kogawa, K., *et al.*, 2002. Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. *Br. J. Hematol.*, 118: 584-588.
- Kurtoglu, E., Kayacetin, E., Ugur, A. 2004. Helicobacter pylori infection in patients with autoimmune thrombocytopenic purpura. *World J. Gastroenterol.*, 10: 2113-2115.
- Liebman, H. 2007. Other immune thrombocytopenias. *Semin. Hematol.*, 44: S24-S34.
- Luzza, F., Imeneo, M., Maletta, M., *et al.*, 1998. Suggestion against an oral-oral route of transmission for Helicobacter pylori infection: a sero-epidemiological study in a rural area. *Dig. Dis. Sci.*, 43: 1488-1492.
- Marshall, B.J., Warren, J.R. 1984. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet*, 1: 1311-1315.
- Michel, M., Khellaf, M., Desforges, L., *et al.*, 2002. Autoimmune thrombocytopenic purpura and Helicobacter pylori infection. *Arch. Intern. Med.*, 162: 1033-1036.
- Poddar, U., Yaccha, S.K. 2007. Helicobacter pylori in children: An Indian perspective. *Indian Pediatr.*, 44: 761-770.
- Rizzo, R., Bortolotti, D., Bolzani, S., Fainardi, E. 2014. HLA-G molecules in autoimmune diseases and infections. *Front. Immunol.*, 18: 592.
- Sherman, P.M., Lin F.Y. 2005. Extra-digestive manifestation of helicobacter pylori infection in children and adolescents. *Can. J. Gastroenterol.*, 19: 421-424.

- Shmueli, H., Domniz, N., Yahav, J. 2016. Non-pharmacological treatment of helicobacter pylori. *World J. Gastrointest. Pharmacol. Ther.*, 7: 171-178.
- Shukla, S., Pujani, M., Agarwal, A., *et al.*, 2012. Correlation of serology with morphological changes in gastric biopsy in Helicobacter Pylori infection and evaluation of immuno-histochemistry for *H. pylori* identification. *Saudi J. Gastroenterol.*, 18: 369–374.
- Stasi, R., Willis, F., Shannon, M.S., *et al.*, 2009. Infectious causes of chronic immune thrombocytopenia. *Hematol. Oncol. Clin. North Am.*, 23: 1275–1297.
- Wong, F., Rayner-Hartley, E., Byrne, M.F. 2014. Extra-intestinal manifestations of helicobacter pylori: a concise review. *World J. Gastroenterol.*, 20: 11950-11961.
- Zhong, Y., Anderl, F., Kruse, T., *et al.*, 2016. Helicobacter pylori HP0231 influences bacterial virulence and is essential for gastric colonization. *PLoS One*, 11: e0154643.

How to cite this article:

Nesren F. Hanafi and Doreen N. Younan. 2017. Prevalence of *Helicobacter pylori* Antibodies in Egyptians with Idiopathic *Thrombocytopenic purpura* and In the General Egyptian Population: A Comparative Study. *Int.J.Curr.Microbiol.App.Sci.* 6(5): 2482-2492.
doi: <https://doi.org/10.20546/ijcmas.2017.605.278>